Nasdaq · Biotech stocks database
CNSP (CNS Pharmaceuticals Inc.) stock: $3.98, $5.8M market cap, $20.0M cash, -$14.2M EV, $105.6M fully diluted market cap. Lead program: Berubicin (Glioblastoma Multiforme, Adult), Phase 2. Data from Fully Diluted's biotech stocks database.
CNS Pharmaceuticals, Inc. (“CNS,” the “Company,” “we,” “us,” or “our”) is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant unmet medical need.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $20.0M |
|---|---|
| Debt | $0.0M |
| Net cash | $20.0M |
| Enterprise value | -$14.2M |
| Basic shares | 20.5M shares |
| Fully diluted shares | 26.5M shares |
| Fully diluted market cap | $105.6M |
| Cash per share | $0.97 |
| Quarterly burn | $3.5M |
| Cash runway | 5.6 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading CNSP daily closes…